Last update March 7, 2021
Very Low Risk
Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of high blood pressure and heart failure.
Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, Serrano 2015, Rush 1991, Redman 1990, Kirsten 1998, Huttunen 1989) and no problems have been observed in infants whose mothers were taking it (Anderson 2018, Rush 1991, Huttunen 1989 ), nor problems in the establishment of breastfeeding (Bach 1995).
It use is authorized in small infants and, off-label, in neonates. (FDA 2018, Kirsten 1998)
Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in the case of prematurity. (Serrano 2015).
Expert authors and medical associations such as the American Academy of Pediatrics consider it to be a drug which is usually compatible with breastfeeding (Ghelfi 2021, Serrano 2015, Rowe 2013, Dennis 2012, Ghanem 2008, AAP 2001, Kirsten 1998).
The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).
We do not have alternatives for エナラプリル since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM